A rationale for age-adapted immunosuppression in organ transplantation

Transplantation

Volumn 99, Issue 11, 2015, Pages 2258-2268

  Krenzien, Felix ^a,b   ElKhal, Abdallah ^a   Quante, Markus ^a,b   Biefer, Hector Rodriguez Cetina ^a   Hirofumi, Uehara ^a   Gabardi, Steven ^a   Tullius, Stefan G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIMETABOLITE; BELATACEPT; BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; CORTICOSTEROID; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADAPTIVE IMMUNITY; AGE DISTRIBUTION; AGING; BACTERIAL INFECTION; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; ELDERLY CARE; GRAFT RECIPIENT; HEALTH IMPACT ASSESSMENT; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; ADVERSE EFFECTS; AGE; ANIMAL; COMORBIDITY; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MIDDLE AGED; PATIENT SELECTION; PREDICTIVE VALUE; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

AGE FACTORS; AGING; ANIMALS; COMORBIDITY; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; ORGAN TRANSPLANTATION; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84945954234     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000842     Document Type: Review

References (139)

1. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 Annual Data Report: Kidney. Am J Transplant. 2014;14(S1):11-44.
2. Eurotransplant International Foundation. Annual Report 2013; 2013.
3. Danovitch GM, Cohen DJ, Weir MR, et al. Current status of kidney and pancreas transplantation in the United States, 1994-2003. Am J Transplant. 2005;5(4 Pt 2):904-915.
4. Watt KD, Pedersen RA, Kremers WK, et al. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroen-terology. 2009;137:2010-2017.
5. Karim A, Farrugia D, Cheshire J, et al. Recipient age and risk for mortality after kidney transplantation in England. Transplantation. 2014;97:832-838.
6. Meier-Kriesche HU, Ojo AO, Hanson JA, et al. Exponentially increased risk of infectious death in older renal transplant recipients. Kidney Int. 2001;59:1539-1543.
7. Jacobson PA, Schladt D, Oetting WS, et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012;12:3326-3336.
8. Tullius SG, Milford E. Kidney allocation and the aging immune response. N Engl J Med. 2011;364:1369-1370.
9. Zetterman RK, Belle SH, Hoofnagle JH, et al. Age and liver transplantation: a report of the Liver Transplantation Database. Transplantation. 1998;66:500-506.
10. Kaczmarek I, Sadoni S, Schmoeckel M, et al. The need for a tailored im-munosuppression in older heart transplant recipients. J Heart Lung Transplant. 2005;24:1965-1968.
11. Dharnidharka VR, Agodoa LY, Abbott KC. Risk factors for hospitalization for bacterial or viral infection in renal transplant recipients-an analysis of USRDS data. Am J Transplant. 2007;7:653-661.
12. Shao M, Wan Q, Xie W, et al. Bloodstream infections among solid organ transplant recipients: epidemiology, microbiology, associated risk factors for morbidity and mortality. Transplant Rev (Orlando). 2014;28:176-181.
13. Candel FJ, Grima E, Matesanz M, et al. Bacteremia and septic shock after solid-organ transplantation. Transplant Proc. 2005;37:4097-4099.
14. Dharnidharka VR, Caillard S, Agodoa LY, et al. Infection frequency and profile in different age groups of kidney transplant recipients. Transplantation. 2006;81:1662-1667.
15. Page Le, Amelia K, Mackie FE, et al. Cytomegalovirus & Epstein Barr Virus serostatus as a predictor of the long-term outcome of kidney transplantation. Nephrology (Carlton, Vic.). 2013;18:813-819.
16. Silveira FP, Husain S. Fungal infections in solid organ transplantation. Med Mycol. 2007;45:305-320.
17. Ok Atilgan A, Özdemir BH, Kirnap M, et al. Invasive fungal infections in liver transplant recipients. Exp Clin Transplant. 2014;12(Suppl 1): 110-116.
18. Kauffman CA. Fungal infections in older adults. Clin Infect Dis. 2001;33: 550-555.
19. AlBugami M, Kiberd B. Malignancies: pre and post transplantation strategies. Transplant Rev (Orlando). 2014;28:76-83.
20. Peev V, Reiser J, Alachkar N. Diabetes mellitus in the transplanted kidney. Front Endocrinol. 2014;5:141.
21. Pham PT, Pham PT, Pham SV, et al. New onset diabetes after transplantation (NODAT): an overview. Diabetes Metab Syndr Obes. 2011;4: 175-186.
22. Hoehn RS, Singhal A, Wima K, et al. Effect of pretransplant diabetes on short-term outcomes after liver transplantation: a national cohort study. Liver Int. 2015;35:1902-1909.
23. Fulop T, Larbi A, Witkowski JM, et al. Immunosenescence and cancer. Crit Rev Oncog. 2013;18:489-513.
24. Weinberger B, Grubeck-Loebenstein B. Vaccines for the elderly. Clin Microbiol Infect. 2012;18(Suppl 5):100-108.
25. Lynch HE, Goldberg GL, Chidgey A, et al. Thymic involution and immune reconstitution. Trends Immunol. 2009;30:366-373.
26. Naylor K, Li G, Vallejo AN, et al. The influence of age on Tcell generation and TCR diversity. J Immunol. 2005;174:7446-7452.
27. Hong MS, Dan JM, Choi J, et al. Age-associated changes in the frequency of naïve, memory and effector CD8+ T cells. Mech Ageing Dev. 2004;125:615-618.
28. Saule P, Trauet J, Dutriez V, et al. Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4(+) versus effector memory and terminally differentiated memory cells in CD8(+) compartment. Mech Ageing Dev. 2006;127:274-281.
29. Brzezinska A, Magalska A, Szybinska A, et al. Proliferation and apoptosis of human CD8(+)CD28(+) and CD8(+)CD28(-) lymphocytes during aging. Exp Gerontol. 2004;39:539-544.
30. Aubert G, Baerlocher GM, Vulto I, et al. Collapse of telomere homeosta-sis in hematopoietic cells caused by heterozygous mutations in telome-rase genes. PLoS Genet. 2012;8:e1002696.
31. Chou JP, Effros RB. T cell replicative senescence in human aging. Curr Pharm Des. 2013;19:1680-1698.
32. Larbi A, Cabreiro F, Zelba H, et al. Reduced oxygen tension results in reduced human T cell proliferation and increased intracellular oxidative damage and susceptibility to apoptosis upon activation. Free Radic Biol Med. 2010;48:26-34.
33. Frasca D, Diaz A, Romero M, et al. Age effects on B cells and humoral immunity in humans. Ageing Res Rev. 2011;10:330-335.
34. Herrero C, Marqués L, Lloberas J, et al. IFN-gamma-dependent transcription of MHC class II IA is impaired in macrophages from aged mice. J Clin Invest. 2001;107:485-493.
35. Oberhuber R, Heinbokel T, Rodriguez Cetina Biefer H, et al. CD11c+ DCs Accelerate the Rejection of Older Cardiac Transplants via IL-17A. Circulation. doi:10.1161/CIRCULATIONAHA.114.014917. May 8, 2015 [Epub ahead of print].
36. Demers P, Moffatt S, Oyer PE, et al. Long-term resultsof heart transplantation in patients older than 60 years. J Thorac Cardiovasc Surg. 2003; 126:224-231.
37. Tullius SG, Tran H, Guleria I, et al. The combinationof donor and recipient age is critical in determining host immunoresponsiveness and renal transplant outcome. Ann Surg. 2010;252:662-674.
38. Frei U, Noeldeke J, Machold-Fabrizii V, et al. Prospective age-matching in elderly kidney transplant recipients-a 5-year analysis of the Eurotransplant Senior Program. Am J Transplant. 2008;8:50-57.
39. Aalami OO, Fang TD, Song HM, et al. Physiological featuresof aging persons. Arch Surg. 2003;138:1068-1076.
40. Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem. 2010;17:571-584.
41. Wooten JM. Pharmacotherapy considerations in elderly adults. South Med J. 2012;105:437-445.
42. Zulman DM, Sussman JB, Chen X, et al. Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med. 2011;26:783-790.
43. US Government Accountability Office. Prescription Drugs: FDA Guidance and Regulations Related to Data on Elderly Persons in Clinical Drug Trials: GAO-07-47R. Washington, DC; 2007.
44. Scott IA, Guyatt GH. Cautionary tales in the interpretation of clinical studies involving older persons. Arch Intern Med. 2010;170:587-595.
45. Blosser CD, Huverserian A, Bloom RD, et al. Age, exclusion criteria, and generalizability of randomized trials enrolling kidney transplant recipients. Transplantation. 2011;91:858-863.
46. Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268:6077-6080.
47. Kaplan B, Lown K, Craig R, et al. Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. Transplantation. 1999;67:333-335.
48. Christians U. Transport proteins and intestinal metabolism: P-glycoprotein and cytochrome P4503A. Ther Drug Monit. 2004;26:104-106.
49. George J, Byth K, Farrell GC. Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol. 1995;50:727-730.
50. Warrington JS, Greenblatt DJ, von Moltke LL, et al. Age-related differences in CYP3A expression and activity in the rat liver, intestine, and kidney. J Pharmacol Exp Ther. 2004;309:720-729.
51. Dai Y, Iwanaga K, Lin YS, et al. In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol. 2004;68:1889-1902.
52. Passey C, Birnbaum AK, Brundage RC, et al. Dosing equation for tacro-limus using genetic variants and clinical factors. Br J Clin Pharmacol. 2011;72:948-957.
53. Miura M, Satoh S, Kagaya H, et al. No impact of age on dose-adjusted pharmacokinetics of tacrolimus, mycophenolic acid and prednisolone 1 month after renal transplantation. Eur J Clin Pharmacol. 2009;65: 1047-1053.
54. Roy J, Lajoie J, Zijenah LS, et al. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos. 2005;33:884-887.
55. Vilas-Boas V, Silva R, Gaio AR, et al. P-glycoprotein activity in human Caucasian male lymphocytes does not follow its increased expression during aging. Cytometry A. 2011;79:912-919.
56. Brenner SS, Klotz U. P-glycoprotein function in the elderly. Eur J Clin Pharmacol. 2004;60:97-102.
57. Falck P, Asberg A, Byberg K, et al. Reduced elimination of cyclosporine A in elderly (65 years) kidney transplant recipients. Transplantation. 2008; 86:1379-1383.
58. Zahir H, McCaughan G, Gleeson M, et al. Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol. 2004;57:298-309.
59. Størset E, Holford N, Midtvedt K, et al. Importance of hematocrit for a ta-crolimus target concentration strategy. Eur J Clin Pharmacol. 2014;70: 65-77.
60. Robertsen I, Åsberg A, Ingerø AO, et al. Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed. Transplantation. 2015;99:528-532.
61. Heit JJ, Apelqvist AA, Gu X, et al. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature. 2006;443:345-349.
62. Shah T, Kasravi A, Huang E, et al. Risk factors for development of new-onset diabetes mellitus after kidney transplantation. Transplantation. 2006;82:1673-1676.
63. Heisel O, Heisel R, Balshaw R, et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant. 2004;4:583-595.
64. Silva HT, Yang HC, Meier-Kriesche H, et al. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. Transplantation. 2014;97:636-641.
65. Haddad EM, McAlister VC, Renouf E, et al. Cyclosporin versus tacroli-mus for liver transplanted patients. Cochrane Database Syst Rev. 2006: CD005161.
66. Pahlavani MA, Vargas DM. Influence of aging and caloric restriction on activation of Ras/MAPK, calcineurin, and CaMK-IV activities in rat Tcells. Proc Soc Exp Biol Med. 2000;223:163-169.
67. Whisler RL, Beiqing L, Chen M. Age-related decreases in IL-2 production by human Tcells are associated with impaired activation of nuclear tran-scriptional factors AP-1 and NF-AT. Cell Immunol. 1996;169:185-195.
68. Lindholm A. Factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monit. 1991;13:465-477.
69. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosup-pression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 2005;80:883-889.
70. Fischer L, Klempnauer J, Beckebaum S, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation-PROTECT. Am J Transplant. 2012;12: 1855-1865.
71. Tateishi T, Nakura H, Asoh M, et al. A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. Life Sci. 1997;61:2567-2574.
72. Zimmerman JJ, Lasseter KC, Lim H, et al. Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment. J Clin Pharmacol. 2005;45:1368-1372.
73. Kovarik JM, Sabia HD, Figueiredo J, et al. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin Pharmacol Ther. 2001;70:425-430.
74. Johnston O, Rose CL, Webster AC, et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol. 2008;19:1411-1418.
75. Flechner SM, Glyda M, Cockfield S, et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant. 2011;11: 1633-1644.
76. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev. 2004;56:163-184.
77. Woo J, Chan HS, Or KH, et al. Effect of age and disease on two drug binding proteins: albumin and alpha-1-acid glycoprotein. Clin Biochem. 1994;27:289-292.
78. Tredger JM, Brown NW, Adams J, et al. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transpl. 2004;10:492-502.
79. van Hest RM, Mathot RA, Pescovitz MD, et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol. 2006;17: 871-880.
80. Kees MG, Steinke T, Moritz S, et al. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycopheno-late sodium in healthy volunteers. J Clin Pharmacol. 2012;52: 1265-1272.
81. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46:13-58.
82. Czock D, Keller F, Rasche FM, et al. Pharmacokinetics and phar-macodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44:61-98.
83. Sæves I, Line P, Bergan S. The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. Ther Drug Monit. 2012;34:452-459.
84. Kawai S, Ichikawa Y, Homma M. Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal diseases: accelerated metabolism of dexamethasone in renal failure. J Clin Endocrinol Metab. 1985;60:848-854.
85. Booker BM, Magee MH, Blum RA, et al. Pharmacokinetic and pharma-codynamic interactions between diltiazem and methylprednisolone in healthy volunteers. Clin Pharmacol Ther. 2002;72:370-382.
86. Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole onthe pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol. 2001;51:443-450.
87. Shimada T, Terada A, Yokogawa K, et al. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation. 2002;74:1419-1424.
88. Bergmann TK, Barraclough KA, Lee KJ, et al. Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation. Clin Pharmacokinet. 2012;51:711-741.
89. Stuck AE, Frey BM, Frey FJ. Kinetics of prednisolone and endogenous cortisol suppression in the elderly. Clin Pharmacol Ther. 1988;43: 354-362.
90. Tornatore KM, Logue G, Venuto RC, et al. Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. J Clin Pharmacol. 1997;37:304-311.
91. Penfornis A, Kury-Paulin S. Immunosuppressive drug-induced diabetes. Diabetes Metab. 2006;32(5 Pt 2):539-546.
92. Midtvedt K, Hjelmesaeth J, Hartmann A, et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol. 2004;15:3233-3239.
93. Zhou Z, Shen J, Hong Y, et al. Time-varying belatacept exposure and its relationship to efficacy/safety responses in kidney-transplant recipients. Clin Pharmacol Ther. 2012;92:251-257.
94. Agrawal A, Agrawal S, Cao J, et al. Altered innate immune functioning of dendritic cells in elderly humans: a role of phosphoinositide 3-kinase-signaling pathway. J Immunol. 2007;178:6912-6922.
95. Leng Q, Bentwich Z, Borkow G. CTLA-4 upregulation during aging. Mech Ageing Dev. 2002;123:1419-1421.
96. Masson P, Henderson L, Chapman JR, et al. Belatacept for kidney transplant recipients. Cochrane Database Syst Rev. 2014;11:CD010699.
97. Coffey GP, Stefanich E, Palmieri S, et al. In vitro internalization, intracellu-lar transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells. J Pharmacol Exp Ther. 2004;310:896-904.
98. van Bueren Lammerts, Jeroen J, Bleeker WK, et al. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res. 2006;66:7630-7638.
99. Mahbub S, Deburghgraeve CR, Kovacs EJ. Advanced age impairs mac-rophage polarization. J Interferon Cytokine Res. 2012;32:18-26.
100. Kovarik JM, Kahan BD, Rajagopalan PR, et al. Population pharmacoki-netics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. Transplantation. 1999;68:1288-1294.
101. Budde K, Matz M, Dürr M, et al. Biomarkers of over-immunosuppression. Clin Pharmacol Ther. 2011;90:316-322.
102. Steinebrunner N, Sandig C, Sommerer C, et al. Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes-a prospective study. Ann Transplant. 2014;19:32-40.
103. Leogrande D, Teutonico A, Ranieri E, et al. Monitoring biological action of rapamycin in renal transplantation. Am J Kidney Dis. 2007;50: 314-325.
104. Vethe NT, Ali AM, Reine PA, et al. Simultaneous quantification of IMPDH activity and purine bases in lymphocytes using LC-MS/MS: assessment of biomarker responses to mycophenolic acid. Ther Drug Monit. 2014;36:108-118.
105. Ducloux D, Courivaud C, Bamoulid J, et al. Prolonged CD4 T cell lym-phopenia increases morbidity and mortality after renal transplantation. J Am Soc Nephrol. 2010;21:868-875.
106. Ducloux D, Bamoulid J, Courivaud C, et al. Thymic function, anti-thymocytes globulins, and cancer after renal transplantation. Transpl Immunol. 2011;25:56-60.
107. Hricik DE, Nickerson P, Formica RN, et al. Multicenter validationofurinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant. 2013;13:2634-2644.
108. Jackson JA, Kim EJ, Begley B, et al. Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant. 2011;11:2228-2234.
109. Chen Y, Tai Q, Hong S, et al. Pretransplantation soluble CD30 level as a predictor of acute rejection in kidney transplantation: a meta-analysis. Transplantation. 2012;94:911-918.
110. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation. 2006;82:663-668.
111. Schulz-Juergensen S, Burdelski MM, Oellerich M, et al. Intracellular ATP production in CD4+ Tcells as a predictor for infection and allograft rejection in trough-level guided pediatric liver transplant recipients under calcineurin-inhibitor therapy. Ther Drug Monit. 2012;34:4-10.
112. Kasiske BL, Zeier MG, Craig JC, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009; (9 Suppl 3):S1-S155.
113. Gill J, Sampaio M, Gill JS, et al. Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States. Clin J Am Soc Nephrol. 2011;6:1168-1178.
114. Khanmoradi K, Knorr JP, Feyssa EL, et al. Evaluating safety and efficacy of rabbit antithymocyte globulin induction in elderly kidney transplant recipients. Exp Clin Transplant. 2013;11:222-228.
115. Patel SJ, Knight RJ, Suki WN, et al. Rabbit antithymocyte induction and dosing in deceased donor renal transplant recipients over 60 yr of age. Clin Transplant. 2011;25:E250-E256.
116. Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355:1967-1977.
117. Webster AC, Ruster LP, McGee R, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev. 2010;1:CD003897.
118. Haynes R, Harden P, Judge P, et al. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. Lancet. 2014;384:1684-1690.
119. Boffa DJ, Luan F, Thomas D, et al. Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res. 2004;10(1 Pt 1):293-300.
120. Luan FL, Ding R, Sharma VK, et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int. 2003;63:917-926.
121. Gabryová L, Christensen JR, Wu X, et al. Integrated T-cell receptor and costimulatory signals determine TGF-β-dependent differentiation and maintenance of Foxp3+ regulatory T cells. Eur J Immunol. 2011;41:1242-1248.
122. Wang Y, Sparwasser T, Figlin R, et al. Foxp3+ Tcells inhibit antitumor immune memory modulated by mTOR inhibition. Cancer Res. 2014;74: 2217-2228.
123. Charpentier B, Medina Pestana JO, Del C, Rial M, et al. Long-term exposure to belatacept in recipients of extended criteria donor kidneys. Am J Transplant. 2013;13:2884-2891.
124. Andrés A, Budde K, Clavien P, et al. A randomized trial comparing renal function in older kidney transplant patients following delayed versus immediate tacrolimus administration. Transplantation. 2009;88: 1101-1108.
125. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corti-costeroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008;248:564-577.
126. Badowski M, Gurk-Turner C, Cangro C, et al. The impact of reduced im-munosuppression on graft outcomes in elderly renal transplant recipients. Clin Transplant. 2009;23:930-937.
127. Hourmant M, Cesbron-Gautier A, Terasaki PI, et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol. 2005;16:2804-2812.
128. Seveso M, Bosio E, Ancona E, et al. De novo anti-HLA antibody responses after renal transplantation: detection and clinical impact. Contrib Nephrol. 2009;162:87-98.
129. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157-1167.
130. Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation. 2013;95:410-417.
131. Roberts DM, Jiang SH, Chadban SJ. The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. Transplantation. 2012;94:775-783.
132. Tait BD, Süsal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation. 2013;95:19-47.
133. Chen H, Chen B. Clinical mycophenolic acid monitoring in liver transplant recipients. World J Gastroenterol. 2014;20:10715-10728.
134. Süsal C, Döhler B, Opelz G. Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report. Hum Immunol. 2009;70:569-573.
135. Koefoed-Nielsen PB, Gesualdo MB, Poulsen JH, et al. Blood tacrolimus levels and calcineurin phosphatase activity early after renal transplantation. Am J Transplant. 2002;2:173-178.
136. Millán O, Brunet M, Campistol JM, et al. Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophe-nolate mofetil. Clin Chem. 2003;49:1891-1899.
137. Hoerning A, Wilde B, Wang J, et al. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity. Transplantation. 2014.
138. Sanquer S, Breil M, Baron C, et al. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin Pharmacol Ther. 1999;65:640-648.
139. Vafadari R, Quaedackers ME, Kho MM, et al. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients. Transplantation. 2012;94:465-472.